Drug Profile
Ciclosporin liposomal - Breath Therapeutics
Alternative Names: Ciclosporin inhalation - Breath Therapeutics; Cyclosporine A Inhalation - Breath Therapeutics; L-CsA - Breath Therapeutics; L-CsA-i; Liposomal cyclosporine A - Breath TherapeuticsLatest Information Update: 04 May 2023
Price :
$50
*
At a glance
- Originator PARI
- Developer Breath Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bronchiolitis obliterans
- Phase II COVID-19 pneumonia
Most Recent Events
- 01 May 2023 Breath Therapeutics completes a phase III BOSTON-1 trial in Bronchiolitis Obliterans in Austria, Belgium, France, Germany, Israel, Spain, USA and the UK (Inhalation)
- 01 May 2023 Breath Therapeutics completes a phase III BOSTON-2 trial in Bronchiolitis Obliterans in Austria, Belgium, France, Germany, Israel, Spain, USA and the UK (Inhalation)
- 18 Mar 2022 Breath Therapeutics terminates the phase II BOSTON-4 trial for Bronchiolitis Obliterans in France, Germany and Spain due to the low number of patients recruitment and the slow enrollment pace of patients (Inhalation) (NCT04107675)